ArticleNuclear medicine and molecular imaging2018
Prognostic Value of Pre- and Post-Treatment FDG PET/CT Parameters in Small Cell Lung Cancer Patients.
Article in Nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2019Trial
- Imaging of Small Cell Lung Cancer: An Updated Overview of Current and Emerging Applications.Radiology. Imaging cancer · 2026Review
- [18F]FDG-PET/CT-based evaluation of tumor response kinetics during induction chemotherapy and concurrent radiochemotherapy in stage II - III small-cell lung cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Evaluation of Semiautomatic and Deep Learning-Based Fully Automatic Segmentation Methods on [Journal of digital imaging · 2023Article
- Molecular Characterization and Therapeutic Approaches to Small Cell Lung Cancer: Imaging Implications.Radiology · 2022Review
- The Use ofDiagnostics (Basel, Switzerland) · 2022Article
- Progress and future prospective of FDG-PET/CT imaging combined with optimized procedures in lung cancer: toward precision medicine.Annals of nuclear medicine · 2022Review
- ComprehensiveFrontiers in immunology · 2022Article
- One Versus Up-to-5 Lesion Measurements for Response Assessment by PERCIST in Patients with Lung Cancer.Nuclear medicine and molecular imaging · 2021Article
- Prognostic Value ofDiagnostics (Basel, Switzerland) · 2021Review
- Primary tumor standardized uptake value (SUVmax) measured onJournal of cancer research and clinical oncology · 2020Article
- Recent advances of PET imaging in clinical radiation oncology.Radiation oncology (London, England) · 2020Review
- Prognostic value ofThe Journal of international medical research · 2020Article
- Application of radiography of computed tomography in non-small cell lung cancer using prognosis model.Saudi journal of biological sciences · 2020Article
- Article
- A New Prognostic Index Combines the Metabolic Response and RECIST 1.1 to Evaluate the Therapeutic Response in Patients With Non-Small Cell Lung Cancer.Frontiers in oncology · 2020Article
- Inverse Prognostic Relationships ofNuclear medicine and molecular imaging · 2018Article
- Diagnostic and Prognostic Applications of PET/CT in Small-cell Lung Cancer.Cancer diagnosis & prognosisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the prognostic value of PET parameters obtained from pre- and post-treatment FDG PET/CT examinations in patients with SCLC.
methodsFifty-nine patients with initially diagnosed SCLC from 2009 to 2014 were included and had chemotherapy and/or concurrent chemoradiotherapy. FDG PET/CT examinations were performed before (PET1) and after (PET2) treatment to evaluate treatment response. A region of interest was placed over the primary lesion and metastatic lymph nodes within the thoracic cavity. PET parameters including change from PET1 to PET2 (Δ in %) were acquired: SUVmax, SUVpeak, MTV2.5, TLG, ΔSUVmax, ΔSUVpeak, ΔMTV and ΔTLG. Patient characteristics including staging, age, sex, LDH and response evaluation by RECIST were surveyed. Statistical analysis was done using Kaplan-Meier method and Cox regression analysis with respect to OS and PFS.
resultsThe median follow-up was 9.6 months (2.5-80.5 months). 27 patients were LD and 32 were ED. Forty-six patients (78.0%) had died, and median OS was 8.6 months; 51 patients (86%) showed disease progression, and median PFS was 2.5 months. On univariate analysis, patients with ED, high interval change (ΔSUVmax and ΔSUVpeak) and low PET2 parameters showed longer OS and PFS. Multivariate analyses demonstrated that ΔSUVpeak (HR 2.6,
conclusionsMetabolic and volumetric PET parameters obtained from pre- and post-treatment FDG PET/CT examinations in patients with SCLC have significant prognostic information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.